Biopharmaceutical companies are increasingly challenged to create a drug pricing strategy that both rewards value and innovation, and promotes affordability and access. During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues, including:

  • US policy and regulatory changes and implications for manufacturers
  • Market access and pricing issues in global markets
  • Contracting and reimbursement models
  • Price transparency
  • Patient affordability

Individuals working in biopharma commercial, pricing and reimbursement, market access, risk and regulatory, and emerging products (such as gene therapies, orphan drugs and digital therapeutics) will benefit from case examples and market analyses of drug pricing challenges, as well as opportunities to improve pricing practices for new and marketed products.

Featured Speakers

Ben Comer

Senior Manager
PwC

Ben covers pharmaceutical and life sciences issues for PwC’s Health Research Institute.

Philip Sclafani

Partner
PwC

Philip is a Partner in PwC’s Pharmaceutical and Life Sciences practice with deep experience supporting branded, biotech (specialty & oncology), generics, medical device, and other healthcare companies.

Karla Anderson

Partner
PwC

Karla is a Partner in PwC’s Advisory Pharmaceutical and Life Sciences Group within the commercial practice. She has over 30 years of experience in the healthcare industry.

NOW AVAILABLE ON-DEMAND

Register now for this webinar